

# The Journal of Rheumatology

VOLUME 43: NO. 9

jrheum.org

SEPTEMBER 2016

## Editorial

**A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?**  
*D. Launay* ..... 1619

## Articles

**Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with RA**  
*E. Ikdahl, S. Rollefstad, G. Wibetoe, et al* ..... 1622

**ACR/EULAR Definitions of Remission Are Associated with Lower Residual Inflammatory Activity Compared with DAS28 Remission on Hand MRI in RA**  
*M.P. Lisbona, A. Solano, J. Ares, M. Almirall, T.C. Salman-Monte, J. Maymó* ..... 1631

**Tofeformant, A Histamine H4 Receptor Antagonist, in Patients with Active RA Despite MTX Therapy: Results of 2 Phase II Studies**  
*R.L. Thurmond, A. Greenspan, W. Radziszewski, et al* . . 1637

**Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in RA: Results from an Australian Early Arthritis Cohort**  
*N.T. Wabe, M.J. Sorich, M.D. Wechalekar, et al* ..... 1643

**Infection in Southern Chinese Patients with SLE: Spectrum, Drug Resistance, Outcomes, and Risk Factors**  
*D. Chen, J. Xie, H. Chen, et al* ..... 1650

**Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in SLE**  
*C. Mora, J. Medina-Rosas, A.M. Santos, et al* ..... 1657

**The Recurrence of Digital Ulcers in Patients with SSc after Discontinuation of Oral Treprostinil**  
*A.A. Shah, E. Schioppa, S. Chatterjee, et al* ..... 1665

**An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial**  
*D. Khanna, C. Albera, A. Fischer, et al* 🐦1672

**The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis**  
*M.J. Kviatkovsky, S. Ramiro, R. Landewé, et al* ..... 1680

**Development of a Screening Tool for the Identification of Sacroiliitis in CT Scans of the Abdomen**  
*J. Chan, I. Sari, D. Salonen, R.D. Inman, N. Haroon* . . . 1687

**Involvement of Mucosal-associated Invariant T cells in Ankylosing Spondylitis**  
*E. Hayashi, A. Chiba, K. Tada, et al* ..... 1695

**Serum CRP Levels Demonstrate Predictive Value for Radiographic and MRI Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab**  
*J. Braun, X. Baraliakos, K.G. Hermann, S. Xu, B. Hsu* ..... 1704

**Efficacy of Subcutaneous Secukinumab in Patients with Active PsA Stratified by Prior TNF Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study**  
*A. Kavanaugh, I.B. McInnes, P.J. Mease, et al* ..... 🐦1713

**Attainment of Minimal Disease Activity Using MTX in PsA**  
*B.J. Sheane, A. Thavaneswaran, D.D. Gladman, V. Chandran* ..... 1718

**A Phase III, Randomized, Controlled Trial of Apremilast in Patients with PsA: Results of the PALACE 2 Trial**  
*M. Cutolo, G.E. Myerson, R.M. Fleischmann, et al* ..... 1724

**Gottron Papules and Gottron Sign with Ulceration: A Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis**  
*H. Cao, Q. Xia, M. Pan, et al* ..... 1735

**Widespread Pain and Low Widespread Pain Index Scores among FM-positive Cases Assessed with the 2010/2011 FM Criteria**  
*F. Wolfe, N. Egloff, W. Häuser* ..... 1743

**The Effect of the Presence of FM on Common Clinical Disease Activity Indices in Patients with PsA: A Cross-sectional Study**  
*S. Brikman, V. Furer, J. Wollman, et al* ..... 1749

🐦 Free online via JRheum Full Release option

Contents continued on page xii

---

## Pediatric Rheumatology

**The Systemic JIA Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010–2013**  
*G. Janow, L.E. Schanberg, S. Setoguchi, et al, and the CARRA Legacy Registry Investigators. . . . .* 1755

## Images in Rheumatology

**Unilateral Macular Lymphocytic Arteritis**  
*A. Arana-Guajardo, C. Mendoza-Rodríguez, I. Miranda-Maldonado . . . . .* 1763

## Correspondence

**Defining Low Disease Activity States in PsA Using Novel Composite Disease Instruments**  
*E. Lubrano, F.M. Perrotta. . . . .* 1765

**Reply** *L.C. Coates, P.S. Helliwell. . . . .* 1766

**Mycophenolate Mofetil in Refractory Cutaneous Lupus Erythematosus: No Definitive Evidence**  
*C. Bachmeyer, S. Galmiche, A. Fayand, A. Degachi, S. Georgin-Lavialle. . . . .* 1766

**Reply** *K. Tselios, D.D. Gladman, J. Su, M.B. Urowitz. . . . .* 1767

## Letters

**Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and SSc**  
*L. Fotis, K.W. Baszis, A.J. White, A.R. French. . . . .* 1768

**Development of Nephrotic Syndrome in a Patient with RA Treated with Certolizumab**  
*R.R. Butendieck Jr., T. Bhattacharya, X. Geiger . . . . .* 1770

## Correction

**Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study**  
*E. Lubrano, F.M. Perrotta, M. Manara, et al. . . . .* 1772

**Meetings in Rheumatology . . . . .** x